Recursion Pharmaceuticals
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 2013-11-05
- Employees
- 500
- Market Cap
- $2.1B
- Website
- http://www.recursion.com
- Introduction
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.
A Study of REC-1245 in Participants with Unresectable, Locally Advanced, or Metastatic Cancer
- Conditions
- UnresectableLocally AdvancedMetastatic CancersRelapsed/Refractory Lymphomas
- Interventions
- Drug: REC-1245
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Recursion Pharmaceuticals Inc.
- Target Recruit Count
- 85
- Registration Number
- NCT06678659
- Locations
- ๐บ๐ธ
START Mountain Region, West Valley City, Utah, United States
The Clostridioides Difficile Trial of REC-3964
- Conditions
- Recurrent Clostridioides Difficile Infection
- Interventions
- Drug: REC-3964
- First Posted Date
- 2024-08-05
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Recursion Pharmaceuticals Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT06536465
- Locations
- ๐บ๐ธ
Snake River Research, Idaho Falls, Idaho, United States
๐บ๐ธMontefiore Medical Group - Family Care Center (FCC), Bronx, New York, United States
๐บ๐ธGANJ - Toms River - Ocean Family Gastroenterology, Toms River, New Jersey, United States
A Study of REC-4881 in Participants with Cancers Which Have an AXIN1 or APC Mutation
- Conditions
- AXIN1 Gene MutationAPC Gene MutationSolid Tumor
- Interventions
- Drug: REC-4881
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Recursion Pharmaceuticals Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06005974
- Locations
- ๐บ๐ธ
Sharp Memorial Hospital, San Diego, California, United States
๐บ๐ธSansum Clinic, Santa Barbara, California, United States
๐บ๐ธRocky Mountain Cancer Centers, Denver, Colorado, United States
Evaluate REC-4881 in Patients With FAP
- Conditions
- Familial Adenomatous Polyposis
- Interventions
- Drug: REC-4881Drug: Placebo
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Recursion Pharmaceuticals Inc.
- Target Recruit Count
- 73
- Registration Number
- NCT05552755
- Locations
- ๐บ๐ธ
Medical Associates Research Group, San Diego, California, United States
๐บ๐ธGI Pros, Naples, Florida, United States
๐บ๐ธGastroenterology Health Partners, PLLC, New Albany, Indiana, United States
Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas
- Conditions
- Neurofibromatosis Type 2
- Interventions
- Drug: PlaceboDrug: REC-2282
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Recursion Pharmaceuticals Inc.
- Target Recruit Count
- 92
- Registration Number
- NCT05130866
- Locations
- ๐บ๐ธ
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
๐บ๐ธNicklaus Children's Hospital, Miami, Florida, United States
๐บ๐ธHouse Institute, Los Angeles, California, United States
The Symptomatic Cerebral Cavernous Malformation Trial of REC-994
- Conditions
- Cerebral Cavernous Malformation
- Interventions
- Drug: REC-994Drug: Placebo
- First Posted Date
- 2021-10-20
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Recursion Pharmaceuticals Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT05085561
- Locations
- ๐บ๐ธ
University of Virginia, Charlottesville, Virginia, United States
๐บ๐ธUniversity of Florida, Gainesville, Florida, United States
๐บ๐ธXenoscience Inc, Phoenix, Arizona, United States